- Article
Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors
- Christian U. Blank,
- Deborah J. Wong,
- Thai H. Ho,
- Todd M. Bauer,
- Carrie B. Lee,
- Fabiola Bene-Tchaleu,
- Jing Zhu,
- Xiaosong Zhang,
- Edward Cha and
- Mario Sznol
This Phase Ib study combined programmed death-ligand 1 inhibitor, atezolizumab, with other immunomodulatory agents in locally advanced and metastatic solid tumors. Arms B-D evaluated atezolizumab plus interferon-α, with/without vascular endothe...

